India's nuclear medicine heritage
India's role in radionuclide therapy isn't new. Indian nuclear medicine centers have been doing peptide receptor radionuclide therapy since the early 2000s — in some cases predating the FDA approvals of branded Lu-177 products. The clinical expertise has been building for over two decades.
What's changed in the last few years is global awareness. International patients facing long waits or unaffordable private prices have increasingly looked to India, where specialized Indian centers deliver the same therapies that leading global centers offer — at a fraction of the cost.
What patients are looking for in a global Lu-177 destination
- Cost relief — without sacrificing quality
- Short wait times — Lutetium therapy is most beneficial when started early
- International protocols — same evidence base used at leading centers
- English-fluent care teams — clear medical communication
- End-to-end support — visa, accommodation, in-country logistics
- Continuity with home care — records that integrate with their local oncologist
Indian centers — and ours specifically — have been built around these expectations.
What makes our center in India the choice
Not all Indian Lutetium therapy options are equal. Volume, focus, protocols, and international experience vary significantly between centers. What we've built at our center in India:
- A dedicated Lu-177 practice — not a side service of a larger hospital
- Purpose-built in-house hot lab — fresh Lu-177 PSMA-617 and Lu-177 DOTATATE prepared on-site
- International protocols — VISION, NETTER-1, NETTER-2, PSMAfore evidence base
- Multidisciplinary team — medical oncology, nuclear medicine, radiation safety, pharmacy, nursing
- Dedicated international patient services — visa support, accommodation, language assistance, end-to-end coordination
- Transparent fixed pricing — no surprise bills
- Patients from 22+ countries
The future
We expect global Lu-177 demand to continue rising as evidence supports earlier intervention in prostate cancer (PSMAfore) and as the indication expands to higher- grade NETs (NETTER-2). India's combination of clinical capability and economic advantage is likely to make it a destination for an increasing share of international patients over the coming years.
We'll be part of that — adding new isotopes, deepening protocols, supporting more international patients. If you're among those considering us, we'd be glad to talk.